The effects of long term use of inhaled corticosteroids on linear growth, adrenal function and bone mineral density in children.
In this study we aimed to investigate the long term effects of inhaled steroids on linear growth, adrenal function and bone mineral density. Thirty children with moderate asthma were randomly divided into two groups. Fifteen children (8 boys, 7 girls mean age; 10.6 +/- 2.1) were treated with budesonide (group 1), and 15 (9 boys, 6 girls, mean age; 9.6 +/- 2.4). with fluticasone propionate (group 2). Control group included 30 children. Anthropometric assessment, symptom and medication scores, pulmonary functions, bone mineral density, serum and urine cortisol levels and ACTH stimulation test were evaluated at the beginning of the study and after one year period. Symptom and medication scores, pulmonary functions improved significantly in both groups (p < 0.05). The mean annual growth was similar in group 1 and 2 and control group. Bone mineral density was comparable with control group at the beginning of the study and after one year. Mean serum cortisol level diminished at the end of the therapy but no significant differences were found between the initial and end values in respect to urine cortisol levels and cortisol/creatinine ratio. Of three groups ACTH stimulation test revealed that there were no significant difference between study and control groups. In conclusion, although we did not observed any side effects of inhaled corticosteroids we suggest that children treated with inhaled corticosteroids for a long time should be followed closely with respect to side effects.
Altintas
D Ufuk
DU
Department of Pediatric Allergy-Immunology, Cukurova University, Adana, Turkey.
Karakoc
G Bingol
GB
Can
S
S
Yilmaz
M
M
Kendirli
S Guneser
SG
D000280:Administration, Inhalation; D000293:Adolescent; D000302:Adrenal Cortex / Q000187:drug effects* / Q000378:metabolism; D000324:Adrenocorticotropic Hormone; D000469:Alkaline Phosphatase / Q000097:blood; D000730:Androstadienes / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D015415:Biomarkers; D001827:Body Height / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects*; D019819:Budesonide / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D002118:Calcium / Q000097:blood; D002648:Child; D003404:Creatinine / Q000097:blood; D005260:Female; D000068298:Fluticasone; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000652:urine; D008297:Male; D010758:Phosphorus / Q000097:blood; D012129:Respiratory Function Tests
D000730:Androstadienes; D015415:Biomarkers; D010758:Phosphorus; D019819:Budesonide; D000324:Adrenocorticotropic Hormone; D003404:Creatinine; D000068298:Fluticasone; D000469:Alkaline Phosphatase; D002118:Calcium; D006854:Hydrocortisone